Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc is an advanced clinical-stage biopharmaceutical company engaged in the development and commercialisation of treatments for gastrointestinal diseases. The company has a broad operational footprint that focuses primarily on the US market. Operating in the competitive biotechnology sector, Phathom Pharmaceuticals Inc distinguishes itself by focusing on diseases of the gastrointestinal tract. Its main product candidate, Vonoprazan, is designed to address unmet needs tied to diseases involving stomach acid. The company operates autonomously but maintains a strategic collaboration with Takeda Pharmaceutical Company Limited. Track the share price of PHAT by adding it to your eToro watchlist.